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Practice points:  4 
• Whereas the gold standard in the therapy of Parkinson’s disease is dopamine 5 
supplementation, it fails to exert a disease-modifying effect and can be associated with 6 
severe motor complications. 7 
• Alterations in the glutamatergic neurotransmission contribute to the neurodegenerative 8 
process and to the development of motor symptoms in Parkinson’s disease.  9 
• Amantadine alone or in combination with AMPA receptor blockers ameliorates 10 
levodopa-induced dyskinesias. 11 
• Memantine might be beneficial for the cognitive impairment and dementia in 12 
Parkinson’s disease patients. Moreover, some data point to its possible beneficial 13 
effect in motor symptoms and dyskinesias. Further studies are needed to assess its 14 
efficacy. 15 
• In animal models, riluzole offered neuroprotection, but the clinical trials to date have 16 
not reproduced this beneficial effect. However, further randomized controlled trials 17 
with greater numners of patient are worth considering. 18 
• The kynurenine pathway of the tryptophan metabolism involves both neuroprotective 19 
and neurotoxic compounds, and alterations in their delicate balance may be connected 20 
with neurodegenerative processes. Elevation of the level of the NMDA antagonist 21 
kynurenic acid might be a possible novel disease-modifying therapeutic tool and also 22 
of use for the management of levodopa-induced dyskinesias. 23 
Summary:Oral levodopa is the current baseline therapy in the management of Parkinson’s 24 
disease, but non-motor complications and therapy-related dyskinesias pose an important 25 
challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative 26 
process of Parkinson’s disease and also in the development of levodopa-induced dyskinesias. 27 
This article will discuss the role of NMDA receptors in Parkinson’s disease and their 28 
modulation as a possible therapeutic approach. 29 
 30 
1. Introduction 31 
Parkinson’s disease (PD), the second most common progressive neurodegenerative disorder, 32 
is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars 33 
compacta (SNpc).  Dopamine replacement with oral levodopa, the gold standard in PD 34 
therapy, offers symptomatic relief to the patients, but it is associated with the development of 35 
dyskinesias and it also fails to exert a disease-modifying effect. Levodopa-induced dyskinesia 36 
(LID) is an important cause of disability in PD patients, thereby posing a major challenge in 37 
the clinical management. Although the current widespread use of dopamine receptor agonists 38 
may delay the onset ofLID, it will occur at a later time point in consequence of the 39 
progressive loss of the nigrostriatal dopaminergic function. Dopamine receptor agonists are 40 
additionally associated with a higher risk of non-motor complications, including impulse-41 
control disorders[1], and also fail to modify the disease progression, so that extensive research 42 
is still required to find neuroprotective strategies. Glutamate, the main excitatory 43 
neurotransmitter in the human brain, has been implicated in the pathophysiology of PD at 44 
multiple levels. Alterations in the glutamatergic neurotransimission may contribute to the 45 
neurodegenerative process and to the motor symptoms of PD, while evidence from animal 46 
models further supports a connection with the development of LID[2]. Glutamate receptors 47 
may therefore be a potential therapeutic target for drug development. A number of 48 
compounds that are capable of influencing the glutamatergic neurotransmission are already 49 
under investigation in clinical trials, while some potential molecules have as yet received less 50 
attention. The kynurenine pathway (KP) of the tryptophan metabolism produces both an 51 
NMDA agonist and an antagonist, and influencing this metabolic route could therefore offer a 52 
valuable therapeutic strategy. 53 
 54 
2. Glutamate and NMDA receptors in the pathogenesis of PD 55 
Glutamate, the main excitatory neurotransmitter in the central nervous system (CNS), exerts 56 
its effects through ionotropic and metabotropic receptors. The ionotropic receptors comprise 57 
three distinct subtypes, each of which bears the name of its preferred agonists: N-methyl-D-58 
aspartate (NMDA), kainate and α-amino-3-hydroxy-5-methylisoxazole-4-proprionicacid 59 
(AMPA). NMDA receptors are involved in such physiological functions as cognition and 60 
memory processes. However, these receptor subtypes have gained considerable attention 61 
because of their key role in excitotoxic processes, as their overactivation results in an 62 
excessive calcium influx into the cells and finally leads to neuronal injury. Excitotoxic 63 
processes have been demonstrated to contribute to the pathomechanism of both acute and 64 
chronic neurologicaldiseases (e.g. ischemic stroke, Alzheimer’s disease(AD) or Huntington’s 65 
disease (HD)). Glutamate excitotoxicity has been suggested to contribute to the pathogenic 66 
process in PD too, enhancing the effects of oxidative stress and a mitochondrial 67 
dysfunction[3]. Extensive research is therefore under way with the aim of finding 68 
neuroprotective strategies, and NMDA receptors are one of the main targets for drug 69 
development. 70 
LID is considered to be the most important therapy-related complication of PD, as it has a 71 
deteriorating effect onthe quality of life of PD patients. The main pathogenic factors in the 72 
development of LID are the progressive decrease of the nigrostriatal dopamine storage 73 
capacity related to the disease severity, and the discontinuous stimulation of neurons by 74 
levodopa[4]. These factors result in downstream changes in gene expression and protein 75 
synthesis, alterations in the mean neuronal firing rate, and reduced activity in specific brain 76 
regions, finally leading to an abnormal motor cortex activity underlying LID [4-6]. Another 77 
important feature in the pathogenesis of LID is the altered glutamatergic neurotransmission. 78 
The increased activity of glutamate receptors, and the hyperphosphorylation of NMDA 79 
receptors have been confirmed in several animal studies [7, 8]. A growing body of evidence 80 
supports the notion that in PD and LID synaptic alterations occur in the distribution, subunit 81 
composition and phosphorylation of NMDA receptors [9-11]. A study involving a rat model 82 
of PD has demonstrated that the extracellular glutamate level and the gene expression of the 83 
glial glutamate transporter GLT1 are significantly increased after chronic levodopa 84 
administration[12]. Human PET investigations have provided evidence of enhanced NMDA 85 
receptor activity in specific motor cortical areas of the brain of dyskinetic PD patients after 86 
levodopa administration[13]. All these findings point to the role of a relatively enhanced 87 
glutamatergic activity in LID, thereby giving a rationale for the use of glutamate receptor 88 
inhibitorsin the management of PD and LID.  89 
 90 
3. NMDA receptors as potential therapeutic targets 91 
Targeting NMDA receptors might offer multiple benefits in the clinical management of PD, 92 
as a substantial amount of evidence suggests that alterations in the glutamatergic 93 
neurotransmission and in the glutamate receptor function may be involved in the 94 
neurodegenerative process and in the development of the motor complications of PD. 95 
Preclinical studies have indicated that different selective and non-selective glutamate receptor 96 
inhibitors may improve the motor symptoms and dyskinesia in PD. As glutamatergic 97 
alterations have been implicated in the development of levodopa-induced motor 98 
complications, the idea of glutamatergic inhibition emerged early, and a number of glutamate 99 
antagonists have been investigated. However, to date only the weak NMDA antagonist 100 
amantadine has become widely applied for the teratment of dyskinesias; the use of other 101 
NMDA antagonists in PD is limited.  102 
3.1.Amantadine 103 
Amantadine has been demostrated to improve LID symptoms both in the form of acute 104 
intravenous adminsitration, and also as chronic treatment [14-16]. Earlier authors debated the 105 
achievement of a sustained effect of amantadine for LID, but a recent study provided evidence 106 
that the beneficial effect of amantadine treatment for motor complications in PD remains even 107 
after 1 year of continuous therapy, while drug withdrawal results in a worsening of the 108 
dyskinesia[17].  109 
NMDA antagonists may cause adverse side-effects, and determination of the minimal 110 
effective and tolerable dose is therefore an important question in the clinical management. 111 
Combination therapies may offer a solution, and result in even better symptom relief. 112 
Bibbiani et al. demonstrated in different animal models that combination therapy with 113 
amantadine and an AMPA receptor blocker led to a significant reduction in levodopa-induced 114 
motor complications. They also concluded that through the use of combination therapy,lower 115 
doses may be sufficient to relieve the symptoms [18]. The benefits of the combination therapy 116 
of LID with amantadine and an AMPA-receptor antagonistwere likewise demonstrated by 117 
another animal study: topiramate exerted a synergistic effect with amantadine, and their 118 
combination attenuated the dyskinesia more effectively than did either drug alone [19]. 119 
3.2. Memantine 120 
Memantine, another well-known NMDAantagonist, is generally recognized as effective for 121 
the therapy of AD. The presumption of the beneficial effects of memantine for the dementia 122 
associated with PD has been confirmed by several randomized controlled studies[20-22]. 123 
Moreover, memantine therapy may improve not only the cognitive impairment, but also the 124 
motor symptoms of PD. Interestingly, the impact of memantine correlated with the serum 125 
homocysteine level [23]. Another surprising observation from case reports was that 126 
memantine was also able to improve levodopa-induced motor complications [24, 25]. This 127 
observation related to only a small number of patients, and therefore far-reaching 128 
consequencescannot be drawn. However, this observation is in accordance with the preclinical 129 
data concerning  the glutamatergic alterations in the pathomechanism of LID. Further 130 
randomized-controlled studies on larger populations will assess the efficacy of memantine for 131 
the management of levodopa-induced motor complications.  132 
3.3. Riluzole 133 
Riluzole, an inhibitor of glutamaterelease,has been investigated in both preclinical and 134 
clinical studies. In a primate model of PD, riluzole treatment proved to be neuroprotective and 135 
to reduce behavioral changes [26]. In other animal models, riluzole was capable of slowing 136 
down the disease progression and delaying the onset of motor abnormalities[27]. 137 
Unfortunately, the results of clinical studies did not reflect the promising preclinical results 138 
[28]. Certain beneficial effects relating to the disease progression and the duration of the 139 
„ON” state were observed in riluzole-treated patients, but these changes did not reach the 140 
level of statistical significance[29,30]. This could probably be attributed to the small numbers 141 
of patients enrolled in those studies, and further randomized trials on larger populations 142 
therefore appear reasonable for a further assessment of the efficacy of riluzole in PD. 143 
3.4. Kynurenines 144 
The KP is the main metabolic route of tryptophan degradation. The intermediates produced in 145 
this enzymatic cascade, collectively termed kynurenines,includeseveral neuroactive 146 
metabolites (Fig.1). The first step in the KP is the enzymatic degradation of tryptophan by 147 
tryptophan 2,3-dioxygenase or indoleamine 2,3-dioxygenase. The key molecule in this 148 
pathway is L-kynurenine (KYN), which can be metabolized in two alternative ways. The first 149 
branch in the KPinvolves the formation of kynurenic acid (KYNA) by different subtypes of 150 
kynurenine-aminotransferases (KATs). Four types of KATs have been identified so far, each 151 
with slightly different biochemical properties[31]. The other main pathway of KYN 152 
degradation is catalyzed by kynurenine-3-monooxygenase (KMO) to form 3-153 
hydroxykynurenine (3-OH-KYN), which is then further degraded in multiple enzymatic steps 154 
to form the neurotoxic quinolinic acid (QUIN). KYNA displays broad-spectrum endogenous 155 
antagonistic properties on ionotropicexcitatory amino acid receptors of NMDA, AMPA and 156 
kainate types, and it is also a non-competitive inhibitor of 7-nicotinic acetylcholine 157 
receptors[32-34]. More recent studies have provided evidence that KYNA exerts a dose-158 
dependent effect on the AMPA receptors: in low concenterations it facilitates these receptors, 159 
while in a higher concentration range it antagonizes them[35]. KYNA has also been descibed 160 
as a ligand of the G-protein-coupledreceptor GPR35[36]. The multiple modes of action 161 
highlight the complex roles of KYNA in the CNS, suggesting an important regulatory 162 
function in neurotransmission, and it has been also implicated in the modulation of 163 
excitotoxic prcesses and neurodegeneration. On the other hand, the metabolites produced in 164 
the other branch of the KP contribute to free radical production and glutamate excitotoxicity.  165 
 166 
Fig.1 near here  167 
 168 
Alterations in the KP are thought to play an important role in the pathogenesis of 169 
neurodegenerative disorders, such as HD or PD[37, 38]. KYNA, so far the only known 170 
endogenous neuroprotective agent, exerts its effects by inhibiting NMDA receptors and it 171 
attenuates glutamate-mediated excitotoxicity. Another important effect is the inhibition of 7-172 
nicotinic acetylcholine receptors, which results in a decrease in the extracellular glutamate 173 
level, and secondarily in a reduced extracellular dopamine concentration [39, 40].Animal 174 
models of PD have demonstrated decreased KATactivity and lower KYNA levels in specific 175 
brain regions, which may be linked to the neurodegenerative process [41-43]. Likewise, 176 
human post-mortem studies have revealed decreased KYNA levels in the frontal cortex, 177 
putamenand SNpc of PD patients, whereas the 3-OK-KYN level was elevated[44]. These 178 
observations may lead to the assumption that a shift in the KP toward the formation of toxic 179 
compounds and the lower availability of the neuroprotective KYNA may contribute to the 180 
neurodegenerative process underlying the pathomechanism of PD. In accordance with this, 181 
injection of the NMDA antagonist KYNA in an experimental PD model alleviated the 1-182 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms[45]. 183 
However, the systemic administration of KYNA is limited because of its poor ability to cross 184 
the blood-barin barrier[46]. In contrast, coadministration of KYN, the prodrug of KYNA, 185 
together with the organic acid transportinhibitor probenecid resulted in an elevation of the 186 
KYNA level and offered neuroprotection in a 6-hydroxydopamine (6-OHDA) model of PD 187 
[47]. Another possible method is the synthesis of KYNA derivatives with better 188 
pharmacological properties. Acuña-Castroviejo et al. demonstrated the neuroprotective effects 189 
of synthetic kynurenines capable of NMDA antagonism in a MPTP-induced PD model [48]. 190 
Another synthetic KYNA-derivative, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-191 
carboxamide hydrochloride, offered neuroprotection and ameliorated the symptoms in a HD 192 
animal model, suggesting that its effects in other neurodegenerative disorderswould also be 193 
worthy of further investigation[49].  194 
The inhibition of KMOcauses a shift in the KP toward the formation of the NMDA antagonist 195 
KYNA, while the production of neurotoxic metabolites is decreased. KMO inhibitors resulted 196 
in elevated KYNA level and gave rise to beneficial effects in the prevention or reduction of 197 
LID, while they did not attenuate the antiparkinsonian effect of levodopa; these effects 198 
wereassociated with the modulation of NMDA receptors [50, 51]. 199 
 200 
Conclusions and future prespectives 201 
The clinical management of PD patients is often challenging, because the symptoms arising 202 
from progression of the disease from the therapy-induced complications have to be addressed 203 
in parallel. At present there is no effective therapeutic strategy with which to modify the 204 
disease progression. Dementia (an important non-motor complication of PD) and LID are 205 
important features which exert a deteriorating effect on the quality of life of PD patients. 206 
Glutamate-mediated excitotoxicity is suggested to be involved both in the neurodegenerative 207 
process, and in the pathomechanism of the motor and non-motor complications. NMDA 208 
receptor inhibitors might therefore be a valuable target for the development of neuroprotective 209 
strategies, and the amelioration of the motor and non-motor complications. Some of the well-210 
known NMDA inhibitors have already been shownto display beneficial effects in preclinical 211 
and clinical studies; however, the clinical data are in many cases controversial. Further large 212 
clinical trials are therefore needed to assess the efficacy of these drugs. Targeting the KP 213 
might offer promising candidates for drug development. 214 
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